Logo

BMS' Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

Share this

BMS' Zeposia (ozanimod) Receives Health Canada Approval for Relapsing Remitting Multiple Sclerosis

Shots:

  • The approval is based on P-lll SUNBEAM & RADIANCE part B study which involves the assessing of Zeposia (0.92mg and 0.46 mg) vs Avonex (qw- IM) in 1-346 & 1313 patients with RMS for 12 & 24mos. across 158 & 150 sites in 20 & 21 countries respectively
  • Result: relative reduction in ARR (48% & 38%); absolute ARR (0.18 vs 0.35 & 0.17 vs 0.28). reduction in number of T1– weighted GdE (0.16 vs 0.43 & 0.18 vs 0.37); reduction in enlarging T2 brain lesions (1.47 vs 2.84 & 1.84 vs 3.18) respectively
  • Zeposia is the only first line S1P receptor modulator approved in Canada for the treatment of RRMS- acts by decreasing the frequency of clinical exacerbations

Ref: News Wire Canada | Image: BMS

 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions